{'fraction_non_alphanumeric': 0.04431991849210392, 'fraction_numerical': 0.033622007131940905, 'mean_word_length': 5.274760383386582, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Construction of four double gene substitution human × bovine rotavirus reassortant vaccine candidates: Each bears two outer capsid human rotavirus genes, one encoding P serotype 1A and the other encoding G serotype 1, 2, 3, or 4 specificity

Previously four human × bovine rotavirus reassortant candidate vaccines, each of which derived ten genes from bovine rotavirus UK strain and only the outer capsid protein VP7‐gene from human rotavirus strain D (G serotype 1), DS‐1 (G serotype 2), P (G serotype 3), or ST3 (G serotype 4), were developed [Midthun et al., (1985); Journal of Virology 53:949–954; (1986): Journal of Clinical Microbiology 24:822–826]. Such human × bovine reassortant vaccines should theoretically provide antigenic coverage for the four epidemiologically most important VP7(G) serotypes 1, 2, 3, and 4. In an attempt to increase the antigenicity of VP7‐based human × animal reassortant rotavirus vaccines which derive a single VP7‐encoding gene from the human strain and the remaining ten genes from the animal strain, we generated double gene substitution reassortants. This was done by incorporating another protective antigen (VP4) of an epidemiologically important human rotavirus by crossing human rotavirus Wa strain (P serotype 1A), with each of the human × bovine single VP7‐gene substitution rotavirus reassortants. In this way four separate double gene substitution rotavirus reassortants were generated. Each of these reassortants bears the VP4‐envoding gene from human rotavirus Wa strain, the VP7‐encoding gene from human rotavirus strain D, DS‐1, P, or ST3, and the remaining nine genes from bovine rotavirus strain UK. The safety, antigenicity, and protective efficacy of individual components as well as combinations of strains are currently under evaluation. J. Med. Virol. 51:319–325, 1997. © 1997 Wiley‐Liss, Inc.† †This article is a US Government work and, as such, is in the public domain in the United States of America.